Telix Pharma Completes Patient Enrollment In Zircon Phase Iii Kidney Cancer Imaging Study
Telix Pharmaceuticals Limited, A Biopharmaceutical Company, Announces That It Has Dosed The Final Patient And Completed Recruitment Into The Phase Iii Pivotal Study Zircon (Zirconium In Renal Cancer Oncology, Nct03849118) Of Its Investigational Renal (Kidney) Cancer Imaging Agent Tlx250-Cdx (89Zr-Dfo-Girentuximab). This Global Study Has Dosed 300 Patients To Date, Exceeding The Target Enrolment Of 252 Patients, Announced On 8 March 2022.Tlx250-Cdx, Which Has Received
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
